Cargando…
Case Report: Methotrexate and hydroxychloroquine in combination for the treatment of NOD2-mutation-associated Blau syndrome
Mutations in nucleotide binding oligomerization domain containing 2 receptor (NOD2) are associated with Blau syndrome (also known as early-onset sarcoidosis)—a rare autosomal dominant, chronic granulomatous disease that typically presents before 5 years of age. Blau syndrome is characterized by the...
Autores principales: | Jensen, Mary Ellen, Harrell, Katelin, McBride, Jeffrey D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585138/ https://www.ncbi.nlm.nih.gov/pubmed/37868966 http://dx.doi.org/10.3389/fimmu.2023.1279329 |
Ejemplares similares
-
Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function
por: Mao, Liming, et al.
Publicado: (2022) -
NOD2 mosaicism in Blau syndrome
por: Mensa-Vilaro, A, et al.
Publicado: (2015) -
Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome
por: Ueki, Yoko, et al.
Publicado: (2023) -
Potential Benefits of TNF Targeting Therapy in Blau Syndrome, a NOD2-Associated Systemic Autoinflammatory Granulomatosis
por: Matsuda, Tomoko, et al.
Publicado: (2022) -
NOD2 Mutation-Associated Case with Blau Syndrome Triggered by BCG Vaccination
por: Arakawa, Akiko, et al.
Publicado: (2021)